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Friend or Foe for
Cardiac Hypertrophy?MicroRNAs (miRNAs) play an important role in the
pathogenesis of structural alterations of cardiac hy-
pertrophy (1). However, the precise mechanisms of
miRNA-29a in cardiac hypertrophy are still unclear.
A recent report in the Journal by Roncarati et al. (2)
indicated that correlation with left ventricular hy-
pertrophy parameters holds true for only miRNA-
29a, which is signiﬁcantly associated with both
cardiac hypertrophy and ﬁbrosis. This suggests that
miRNA-29a is a potential therapeutic target for car-
diac hypertrophy.
Other studies have found that down-regulation of
miRNA-29a is associated with pathological cardiac
hypertrophy. Abonnenc et al. (3) showed that levels
of miRNA-29a were signiﬁcantly reduced in a mouse
model of pathological but not physiological hyper-
trophy (3). Furthermore, Divakaran et al. (4) indi-
cated that Smad3 signaling plays dual roles in the
heart: a beneﬁcial role by delimiting hypertrophic
growth and a deleterious role by modulating myo-
cardial ﬁbrosis, possibly through a pathway that en-
tails accumulation of miRNA-29a, which decreases
collagen gene expression. However, Zile et al. (5)
showed that miRNA-29a levels increased 5 days after
myocardial infarction and then decreased to control
levels at later time points. A time-dependent change
in miRNA-29a levels occurred in patients
with myocardial infarction, including an early and
robust increase in miRNA levels that affected myo-
cardial ﬁbrosis.
These ﬁndings suggest that miRNA-29a may be
a good clinical biomarker for patients with cardiac
hypertrophy because it seems to play a key role in
the development of this condition. Additional studieswith more patients and animal studies are needed
to determine the precise role of miRNA-29a in car-
diac hypertrophy, and therapeutic agents targeting
miRNA-29a might result in innovative new therapies.
All in all, we greatly enjoyed reading the article by
Roncarati et al. (2) and believe that miRNA-29a may
be useful for the prevention and treatment of cardiac
hypertrophy.Hui Tao, MD
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Interleukin Genotypes
Potentiate Early and
Advanced Atherosclerosis
DifferentlyWe read with interest the paper by Tsimikas et al.
(1) in a recent issue of the Journal, which reported
that genetic differences in the interleukin (IL)-1 gene
cluster, known to be associated with inﬂammatory
responsiveness, strongly inﬂuence the presence of
